against the FDA’s approval and subsequent deregulation of mifepristone in a Texas federal district court in 2023. The case was challenged all the way to thethat the $700,000 stockpile of the drug has been preserved as the accessibility of the drug remains pending before the Supreme Court.
Currently pending before the court is whether the FDA had the authority in 2021 to remove in-person dispensing requirements for mifepristone, which enabled healthcare providers to provide the pill to patients by mail. Anti-abortion advocates contend that in-person screening requirements before dispensing mifepristone are a key point in preserving the health of the woman to determine the gestational age and to rule out abnormalities, such as a life-threatening ectopic pregnancy.